Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 8/20 | 0.41 |
| ▸ | CDK9 | P50750 | 8/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2982715 | 0.91 | CCNT1 (0.42) | CCNT1CDK9SUV39H2TBK1CCNK | |
| SCHEMBL2985929 | 0.91 | IGF1R (0.38) | CCNT1CDK9 | |
| SCHEMBL2990025 | 0.87 | CCNT1 (0.45) | CCNT1CDK9TBK1 | |
| Hydrochloric Acid SCHEMBL2990404 | 0.85 | IGF1R (0.40) | CCNT1CDK9 | |
| SCHEMBL5529651 | 0.84 | CCNT1 (0.43) | CCNT1CDK9SUV39H2 | |
| SCHEMBL2991812 | 0.82 | TGFBR1 (0.38) | CCNT1CDK9SUV39H2TGFBR1HTR6 | |
| SCHEMBL2991814 | 0.82 | CCNT1 (0.42) | CCNT1CDK9SUV39H2TBK1TGFBR1 | |
| SCHEMBL5538745 | 0.82 | SUV39H2 (0.38) | CCNT1CDK9SUV39H2 | |
| SCHEMBL2987134 | 0.82 | CDK9 (0.39) | CCNT1CDK9 | |
| SCHEMBL5531332 | 0.80 | IGF1R (0.42) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| EP-1799691-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037875-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | CCNT1 327/4885CDK9 90/4885SUV39H2 1845/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | CCNT1 327/4885CDK9 90/4885SUV39H2 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.